Last reviewed · How we verify
Ropinirole XL (formerly CR)
Ropinirole XL is a dopamine agonist that works by stimulating dopamine receptors in the brain.
Ropinirole XL is a dopamine agonist that works by stimulating dopamine receptors in the brain. Used for Treatment of Parkinson's disease, Treatment of restless legs syndrome.
At a glance
| Generic name | Ropinirole XL (formerly CR) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | dopamine agonist |
| Target | D2 receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
This action helps to increase the levels of dopamine in the brain, which can help to alleviate symptoms of Parkinson's disease. Ropinirole XL is a long-acting formulation of the drug, which allows for once-daily dosing.
Approved indications
- Treatment of Parkinson's disease
- Treatment of restless legs syndrome
Common side effects
- Nausea
- Dizziness
- Headache
- Fatigue
- Dyskinesia
Key clinical trials
- An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease (PHASE3)
- Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ropinirole XL (formerly CR) CI brief — competitive landscape report
- Ropinirole XL (formerly CR) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI